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Abstract
Background: In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was introduced in the
Netherlands for all children aged 14 months. Despite its success, herd immunity may wane over time. Recently, a serogroup
A,C,W135,Y meningococcal conjugate vaccine (MenACWY) was licensed for use in subjects of 12 months of age and above.
Objectives: To evaluate the cost-effectiveness of meningococcal vaccination at 14 months and an additional vaccination at
the age of 12 years, both with the MenACWY vaccine.
Methods: A decision analysis cohort model, with 185,000 Dutch newborns, was used to evaluate the cost-effectiveness of
different immunization strategies. For strategies including a vaccination at 12 years of age, an additional cohort with
adolescents aged 12 years was followed. The incremental cost-effectiveness ratio (ICER) was estimated for the current
disease incidence and for a scenario when herd immunity is lost.
Results: Vaccination with MenACWY at 14 months is cost-saving. Vaccinating with MenACWY at 14 months and at 12 years
would prevent 7 additional cases of meningococcal serogroup A,C,W135,Y disease in the birth cohort and adolescent cohort
followed for 99 years compared to the current vaccine schedule of a single vaccination with MenC at 14 months. With the
current incidence, this strategy resulted in an ICER of J635,334 per quality adjusted life year. When serogroup C disease
incidence returns to pre-vaccination levels due to a loss of vaccine-induced herd-immunity, vaccination with MenACWY at
14 months and at 12 years would be cost-saving.
Conclusions: Routine vaccination with MenACWY is cost-saving. With the current epidemiology, a booster-dose with
MenACWY is not likely cost-effective. When herd immunity is lost, a booster-dose has the potential of being cost-effective. A
dynamic model should be developed for more precise estimation of the cost-effectiveness of the prevention of
disappearance of herd immunity.
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Introduction
Neisseria meningitidis (the meningococcus) is an important cause of
bacterial meningitis and septicaemia worldwide [1,2]. Meningo-
coccal disease has a high mortality rate and survivors are at high
risk of having permanent sequelae like mental retardation, hearing
loss, scars and amputations [3,4].
In the Netherlands, routine vaccination at the age of 14 months
with a meningococcal serogroup C conjugate (MenC) vaccine was
implemented in the National Immunization Program (NIP) after a
meningococcal serogroup C disease outbreak in 2000 and 2001.
This implementation was accompanied by a catch-up program for
all children and adolescents aged 1 to 18 years. Hereafter, the
incidence of serogroup C disease decreased considerably [5] and
probably also carriage of serogroup C strains of Neisseria meningitidis
decreased as seen in the United Kingdom (UK) [6,7].
The decreased carriage of serogroup C meningococci has led to
a reduced transmission of the bacterium whereby unvaccinated
individuals are protected. This herd immunity effect might be
partly the reason for the decreased incidence of serogroup C
disease in the Netherlands [8]. High vaccination coverage in the
age group with a likely high meningococcal transmission rate, i.e.
adolescents [9], is a key factor for achieving herd protection [2].
Therefore, the catch-up program likely accounts for the majority
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of the herd immunity effect. However, the adolescent population
of the future may have levels of antibodies which are too low to be
protective against carriage and/or disease since they are vacci-
nated at the age of 14 months and duration of protection is limited
when vaccinating at young age [10]. An unprotected adolescent
population could result in a renewed circulation of serogroup C
meningococci and a considerable reduction in herd immunity.
Therefore, it might be necessary to add a booster-dose early in
adolescence to maintain the herd immunity effect and provide
protection against meningococcal disease in this age group
[11,12].
Consequently, Austria and Switzerland have recently added a
booster-dose with a conjugated MenACWY or MenC vaccine for
children around the age of 12 years in addition to infant
immunization [13,14].
While the incidence of serogroup C meningococcal disease is
currently still low in the Netherlands, the incidence of serogroup Y
disease is increasing, especially in adolescents (Appendix S1) [15].
The quadrivalent conjugate vaccine against serogroup A, C, W135
and Y disease (MenACWY) indicated for use in subjects of 12
months of age or older (Nimenrix, GlaxoSmithKline) was recently
licensed in the European Union [16]. This vaccine is the only
quadrivalent vaccine that is currently licensed in the European
Union for use in children younger than two years of age and could
be used to replace the current MenC vaccination among Dutch
children aged 14 months. The shift from a MenC vaccine to this
MenACWY vaccine in the NIP might prevent additional cases of
meningococcal disease.
In this paper, we present the economic evaluation of routine
vaccination with the MenACWY vaccine at 14 months and the
evaluation of an additional booster-dose with MenACWY early in
adolescence.
Methods
Health effects, costs, savings and the incremental cost-effective-
ness ratios (ICERs) of routine vaccination with the MenACWY
vaccine for infants aged 14 months and of an additional booster-
dose of the MenACWY vaccine at the age of 12 years were
estimated. These strategies are further named ‘MenACWY’ for
only vaccinating at 14 months, and ‘MenACWY+MenACWY’ for
vaccinating at 14 months and 12 years. Both strategies were
compared with the current situation in the Netherlands: vacci-
nating with MenC at 14 months (‘MenC’). The booster-dose
strategy was also compared with MenACWY at 14 months.
According to the Dutch guidelines for pharmacoeconomic
research [17], the study was performed from the societal
perspective. Future costs and health effects were discounted with
respectively 4% and 1.5%. ICERs were calculated by dividing
Figure 1. Decision tree used in the economic model. Squares represent decision nodes, circles represent probabilities and triangles represent
end states. (+) indicates that the decision tree follows the same path as the branch indicated with +.
doi:10.1371/journal.pone.0065036.g001
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incremental costs in euros (J) by quality adjusted life years
(QALYs) gained. All calculations were carried out with Excel 2010
(Microsoft).
Model
A decision tree analytic model was designed to simulate the
different vaccination strategies (fig. 1). A cohort of 185,000 Dutch
newborns [18], was run through the decision tree once per strategy
and for the comparator. For estimation of the ICERs of
vaccinating at 12 years of age, an additional cohort of 200,000
12-year old adolescents was followed [18]. For this separate cohort
of 12-year old adolescents, it was assumed that protection by
vaccination at the age of 14 months was still partly present. In
addition, we removed all children who had meningococcal disease
before the age of 12 years from this cohort. Time cycles of 1
month for children less than 2 years of age and annual cycles for
children above this age were used. The time horizon of the study
was 99 years, taking lifetime costs and effects into account. The
parameters used in the model are shown in table 1 and table 2.
Epidemiology
The incidence of meningococcal serogroup A,C,W135,Y
disease was determined using data from the Netherlands
Reference Laboratory for Bacterial Meningitis (NRLBM, Aca-
demic Medical Center, Amsterdam) (appendix S1) [15,19]. For the
base-case, the average incidence of 2007–2011 was used. For
scenario analyses, the serogroup ACWY incidence of 2011 and the
serogroup C incidence of 2001 were used. Incidences of 2007–
2011 and of 2001 were adjusted for respectively a reporting
percentage of 85–90% and 83.3% [15,20].
Healthcare Resource Use
Based on our previous study [20], we assumed that meningo-
coccal disease without a septic shock requires one general
practitioner visit, microbiological diagnostics, a magnetic reso-
nance imaging scan, antibiotic treatment, 15 days hospitalization
and follow-up visits after recovery. This follow-up includes 2
outpatient consultations of a paediatrician for patients aged less
than 15 years and two general practitioner visits for patients 15
years or older [20]. When disease is accompanied by a septic
shock, instead of 15 days hospitalization, there is a need for 5 days
Table 1. Probability parameters used in the economic model.
Base casea Distribution References
Vaccine parameters
Vaccine efficacy (%)
Initial vaccine efficacy (14 months) 89.96 Triangular (64;89.96;98) [29,30]
Initial vaccine efficacy (12 years) 95.95 Triangular (92;95.95;99) [29,30]
Adverse events
Number of AE per 10,000 immunizations 3.48 Beta (4764;13691736) [48]
Number of AR per 10,000 immunizations 0.02 Beta (27;13696473) [48]
Vaccination coverage (%)
14 months 95.9 Fixed [49]
12 years 94.0 Fixed [50]
Disease parameters
ACWY incidence (per 100,000 persons) 0.15 (age dependent) Beta (25;16431651) [15]
Clinical features (%)
Meningococcal disease 65.1 Beta (443;238) [51,52]
Meningococcal disease with septic shock 34.9 Dependent of MD [51,52]
Case fatality (%)
Case fatality rate MD 2.1 Beta (8;372) [51]
Case fatality rate MDS 13.0 Beta (21;140) [51]
Sequelae (%)
Scars 2.8 Beta (16;546) [4]
Amputations 0.7 Beta (4;558) [4]
Neurological sequelae 6.9 Beta (127;1707) [3,4,39]
Demographic parameters
Birth cohort 185,000 Fixed [18]
Adolescent cohort (aged 12 years) 200,000 Fixed [18]
Probability of being a girl 49.0% Fixed [18]
Probability of being a boy 51.0% Fixed [18]
Probability of dying of other causes Age dependent Fixed [15,18]
AE = adverse event, AR =Anaphylactic reactions, MD=meningococcal disease without septic shock, MDS=meningococcal disease with septic shock.
aValues are presented as percentages or rates.
doi:10.1371/journal.pone.0065036.t001
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intensive care unit, extra medical assistance and 13 days
hospitalization [20].
Patients with meningococcal disease can recover completely,
but the disease can also result in death or sequelae like
neurological sequelae, scars or amputations. We assumed that
25% of the patients with neurological sequelae (i.e. hearing loss,
mental retardation) require lifetime intensive institutional care and
50% of the patients require special education [20]. Other resource
utilization taken into account is the public health follow-up of a
meningococcal case [20].
QALY losses due to permanent sequelae, i.e. amputations, scars
and neurological sequelae were included in the analyses [21]. We
did not take into account QALY losses associated with acute forms
Table 2. Unit costs for resource utilization in euros (J) and other parameters used in the economic model.
Base case Distribution References
Cost parameters (J)
Overhead costs of the immunization program
Routine immunization of toddlers 62,476 Fixed [20]
Booster-dose at the age of 12 years 62,476 Fixed [20]
Vaccine dose
MenACWY 42.72 Fixed [23]
MenC 55.11 Fixed [24]
Other costs
Administration costs routine infant vaccination 6.30 Fixed [20]
Administration costs booster dose 14.50 Fixed [20]
Booster-dose boys invitation 0.50 Fixed [20]
GP visit 29 Fixed [17]
Microbiological diagnostics and MRI 305 Gamma (1;305) [20,53]
Full course of parenteral antibiotic treatment 297 Gamma (1;297) [20]
Inpatient day (general ward) 463 Fixed [17,54]
Inpatient day (intensive care unit) 2,263 Fixed [17]
Extra medical assistance with septic shock 1,879 Gamma (1;1879) [20]
Treatment for scars 506 Gamma (1;506) [20]
Treatment for amputations 1,628 Gamma (1;1628) [20]
Institutional care (annual costs) 90,036 Gamma (1;90036)) [17]
Special education (annual costs) 4,700–13,810 Gamma (age dependent) [18,22]
Pediatrician follow-up 122 Gamma (1;122) [20]
Public health follow-up 62 Gamma (1;62) [20]
Productivity costs (per hour)
Parents 28.74 Gamma (1;29) [17,18]
Children in the cohort 9.51–37.34 Gamma (age dependent) [17]
Other parameters
Duration of hospitalization (days)
Standard hospitalization MD 15 Gamma (1;15) [20]
Standard hospitalization MDS 13 Gamma (1;13) [20]
Intensive care unit MDS 5 Gamma (1;5) [20]
Treatment of scars 2 Gamma (1;2) [20]
Treatment of amputations 8 Gamma (1;8) [20]
Total drop in quality of life (QALY)
Amputations or scars 0.17 Beta (5.20;25.39) [21]
Neurological sequelae 0.25 Beta (10.01;30.02) [21]
Average quality of life general population 0.89 Beta (age dependent) [55]
Discount rates (%)
Costs 4.0 Fixed [17]
Health effects 1.5 Fixed [17]
HPV= human papillomavirus, GP = general practitioner, MD=meningococcal disease without septic shock, MDS =meningococcal disease with septic shock,
MRI =magnetic resonance imaging scan, QALY = quality adjusted life year, NA= not applicable.
doi:10.1371/journal.pone.0065036.t002
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of disease or minor vaccine-related adverse events, because of the
limited duration of these events.
Costs
Direct and indirect costs were considered at 2011 price levels
(table 2). Costs not available at 2011 price levels were inflated to
2011 using Dutch consumer price indices for all costs except for
productivity costs per hour, which were inflated using Dutch
collective labor agreement (CAO) price indices.
Costs for special education were calculated by determining the
age-specific additional costs per child per year for special
education compared to regular education [18,22]. These costs
were calculated for children younger than 16 years of age because
in the Netherlands education is compulsory until that age. Indirect
costs were calculated using the friction cost method [17] (appendix
S2). A vaccine price of respectively J42.72 and J55.11 per dose
for MenACWY and MenC were used according to the current
pharmacy prices [23,24].
Vaccine Characteristics
Due to the lack of studies on the vaccine effectiveness (VE) of a
MenACWY conjugate vaccine in the population and because the
C component in MenACWY is immunologically non-inferior to
that of MenC [25–28], the VE of MenACWY was assumed to be
equal to the MenC vaccine. The VE was estimated by post-
licensure studies about the MenC vaccine in the UK [29,30]. VE
was assumed to wane over time following equation 1:
VE tð Þ~VE 0ð Þ|e {w|tð Þ ð1Þ
Where VE(0) is the VE half a month after vaccination (percent),
w is the annual waning rate and t is the time since protective
immunity started (years). Full protection was assumed half a
month after vaccination. The average duration of protection (1/w)
was set at 4 years for vaccination at 14 months, based on the levels
of protective antibody levels against serogroup C meningococcal
disease among children 5 years after being vaccinated with the
MenC vaccine at the age of 14 months [10]. For vaccination at 12
years, the average duration of protection was varied between 25
years (the base-case) and livelong protection. Experience with the
MenC vaccine showed that for children vaccinated at the age of 12
years, protective antibody levels against serogroup C meningo-
coccal disease were present in more than 80% of children 5 years
after vaccination [10]. If the protective immunity would wane
according to equation 1, approximately 80% of children would
have protective antibody levels 5 years after vaccination, when the
average duration of protection is set at 25 years.
Herd Immunity
In the base-case analyses we conservatively assumed that the
meningococcal C disease incidence would remain stable, despite
waning of the vaccine efficacy, due to herd immunity and a low
force of infection. For protection against serogroup A, W and Y it
was assumed that vaccination with the MenC or MenACWY
vaccine at 14 months would not induce herd immunity.
Consequently, herd immunity effects in unvaccinated cohorts
were assumed to be the same for MenC and MenACWY in the
base-case, thereby applying herd immunity effects to the MenC
incidence only.
For the strategy with MenACWY vaccinations at 14 months
and 12 years, ICERs were calculated with and without herd-
immunity.
Herd-immunity was incorporated in the model in a similar way
as Rozenbaum et al. did [31].The magnitude of the herd-immunity
was obtained by comparing the serogroup C incidence of 2001
with the average serogroup C incidence of 2007–2011. The
incidence declined with 92% in both children between 0 and 1
years of age and in persons aged 27 years and over. As both groups
were not protected by direct vaccination during both periods, this
figure was used as the magnitude of herd-immunity induced by the
vaccination. The decline in other age-groups, assuming a duration
of protection of 5 years for vaccination at 14 months and of 25
years for vaccination at 12 years, was in accordance with a herd-
immunity effect of 95% in age-categories that were also protected
by direct vaccination and of 92% in all other age-groups.
For this scenario it was assumed that vaccination at 12 years
would start at the same time as vaccination with 14 months.
Therefore, a birth cohort, a 12-years old cohort and a cohort with
the rest of the population was followed. Herd-immunity was
accounted for only during the first year of vaccination, as it was
assumed that to sustain the herd-immunity at the same level each
year an additional shot at 12 years was needed, while we modelled
only vaccinations in the first year of the model.
Scenario Analysis
In scenario analysis we calculated what the extra value of
MenACWY compared to MenC in euros was for vaccination at 14
months only at a threshold values of J20,000 and J50,000 per
QALY.
Poor antibody persistence against meningococcal serogroup C
disease following vaccination at a toddler age was observed in the
UK [11]. Therefore, without additional vaccinations at a higher
age, the herd immunity effect invoked by the catch-up campaign
could disappear over time. Consequently, a possible restored
circulation of the bacterium might occur in coming years [11].
Therefore, in a scenario analysis it was estimated what the cost-
effectiveness was of MenACWY+MenACWY compared to
vaccination with MenACWY at 14 months only. To simulate
the effect of the additional vaccination at 12 years of age, it was
assumed that the MenACWY+MenACWY strategy would result
in maintenance of the current meningococcal C disease incidence.
For the strategy with MenACWY at 14 months only it was
assumed that this strategy would result in a serogroup C disease
incidence similar to that seen during 2001, i.e. pre-MenC
vaccination incidence levels minus the estimated direct effect of
MenC vaccination at 14 months without a catch-up campaign.
Consequently, for this scenario it was assumed that MenACWY
has already been implemented and herd immunity against
serogroup C disease was completely disappeared.
For the scenario analysis in which the disappearance of a herd-
immunity effect would be prevented by vaccination at 12 years,
direct and indirect vaccination effects were incorporated.
Sensitivity Analysis
There are two key assumptions that determine the cost-
effectiveness of MenACWY in comparison with MenC: the price
difference and the vaccine effectiveness of both vaccines. Although
the C component in the MenACWY has been shown to be
immunologically non-inferior to that of MenC [25–28], the
duration of protection after MenACWY vaccination is uncertain.
In addition, although the list prices of both vaccines are known
[23,24], the reduced prices for the national immunisation
programme might be different. Therefore, in bivariate sensitivity
analysis, the influence of the price differential and the duration of
protection on the ICER was assessed.
Cost-Effectiveness of MenACWY Vaccination
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In univariate sensitivity analysis, relevant parameters were
varied one at a time using the upper and lower limit of the 95%
confidence intervals of the mean to determine which parameters
had a great influence on the ICER. The vaccine price of
MenACWY and the disease incidence were varied by 25%, as the
degree of uncertainty for these parameters is unclear. Also, the
vaccine effectiveness and discounting rates were varied one by one
to explore their impact. Additionally, we varied the decay function
for the vaccine effectiveness of the booster, thereby using the
function previously used by De Wals et al. [32] and a linear
function, thereby choosing the waning rate in accordance with the
study of De Voer et al. [10].
Because the incidence of meningococcal disease is naturally
fluctuating [33] a threshold analysis was performed to determine
the overall incidence of serogroups A,C,W135,Y meningococcal
disease which is required for vaccination to become cost-effective
at J50,000 per QALY.
To assess the uncertainty of the ICERs, a probabilistic
sensitivity analysis was performed. Parameters were generated
using random sampling within the specified range of the
corresponding distribution of the parameters. Outcome values
were generated by running the model 10,000 times.
Results
Base-case
Vaccinating with MenACWY at 14 months would avoid 1
additional case of meningococcal serogroup A,W135,Y disease for
the birth cohort followed for 99 years, corresponding to a gain of
2.9 QALYs (discounted), and was estimated to be cost-saving
(table 3). Implementing an additional vaccination with Me-
nACWY at 12 years of age would prevent 7 additional cases,
which corresponds to a gain of 12 life years or 15 QALYs when
compared with MenC at 14 months. This strategy has an
additional total cost of about J9.5 million compared with MenC
at 14 months and vaccination costs are about J20.6 million. The
estimated ICER was J635,334 per QALY. Comparing this
booster-dose strategy with MenACWY at 14 months, 6 additional
cases of meningococcal disease are prevented, which corresponds
to a gain of 9 life years and 12 QALYs (table 4). Additional total
costs are approximately J11.7 million. The estimated ICER for
this scenario was J988,490 per QALY.
Assuming herd-immunity could also be invoked for serogroup
AW135Y disease and lifelong protection after vaccination at 12
years or using the most recent disease incidence figures resulted in
lower ICERs, but the ICERs for vaccination at 12 years of age
were still too high to be considered cost-effective (table 3).
With the current low meningococcal C disease in the Nether-
lands, a schedule with vaccinations with MenC at 14 months and
12 years of age resulted in a high ICER of J2,620,329 per QALY,
when compared to the current immunization schedule with a
single vaccination with MenC at 14 months.
Scenario Analysis
Since MenACWY at 14 months is cost-saving compared to
MenC at 14 months mainly due to a lower vaccine price, we also
estimated the extra value of MenACWY compared to MenC in
euros for this scenario. MenACWY could cost J0.41 more than
MenC for a threshold of J20,000 per QALY and J0.90 more at a
threshold of J50,000 per QALY.
As the meningococcal serogroup Y disease incidence is currently
increasing [19] we estimated for which disease incidence
MenACWY+MenACWY would remain below J50,000 per
QALY. Using the base-case assumptions and age-distribution,
the total ACWY disease incidence should be 2.37 per 100,000
persons, when comparing MenACWY+MenACWY with Me-
nACWY at 14 months. Using the age-distribution of 2011, this
threshold incidence would be 1.28 per 100,000 persons (table 3).
The scenario comparing MenACWY+MenACWY with Me-
nACWY when herd immunity disappeared was estimated to be
cost-saving (table 3).
Bivariate and Univariate Sensitivity Analysis
In bivariate sensitivity analyses, when comparing MenC at 14
months with MenACWY at 14 months, the influence of a
difference in the duration of protection of both vaccines and the
price differential was assessed. Assuming that herd immunity is still
present, MenACWY is still cost-saving when the average duration
of protection for MenACWY is 1 year shorter than for MenC (3
vs. 4 year), when the vaccine price per dose is the same for both
vaccines (table 5). However, if herd immunity is lost, and MenC
has returned to pre-vaccination levels, vaccinating with Me-
nACWY at 14 months only would result in a loss of QALYs if the
duration of protection is 1 year shorter for MenACWY.
Univariate sensitivity analyses, for the base-case MenACWY+-
MenACWY compared with MenACWY at 14 months, showed
that the incidence of serogroup A,C,W135,Y disease had a high
impact on the ICER. Also, the vaccine price of MenACWY and
the case fatality rate had quite an impact on the ICER. No
discounting of costs and effects substantially lowers the ICER,
while applying a discount rate of 4% for both costs and effects
dramatically increases the ICER (figure 2).
Probabilistic Sensitivity Analysis
For the base-case, it is unlikely that vaccination with
MenACWY+MenACWY could be considered cost-effective com-
pared to MenC at 14 months as well as to MenACWY at 14
months. The scenario showing the prevention of a decline in herd
immunity has a high probability to be considered cost-effective.
Given the uncertainty of the model, 95% of simulations comparing
MenACWY+MenACWY with MenACWY at 14 months were
found below J1,750 per QALY and 100% below J15,800 per
QALY.
Discussion
Our analysis shows that vaccinating with MenACWY at 14
months is cost-saving compared with the current situation in the
Netherlands. This is mainly due to the lower vaccine price of
MenACWY compared with MenC. Also, the prevention of more
cases of meningococcal disease with MenACWY contributes to the
favourable ICER.
Using our base-case assumptions, adding a booster-dose at 12
years of age with MenACWY in addition to MenACWY at 14
months seems not to be a cost-effective strategy.
Serogroup Y meningococcal disease was rare in Europe but in
recent years an increase in the incidence of serogroup Y
meningococcal disease has been reported [34]. In the Netherlands,
the incidence of serogroup Y meningococcal disease doubled
during the last 5 years, but the number of cases is still low [15].
However, while during 2006–2010 on average 5% of all serogroup
Y cases occurred in adolescents aged 12–19 years, in 2011 33% of
serogroup Y cases occurred in this age-group with a likely high
meningococcal transmission rate [15]. A further increase in the
incidence of serogroup Y disease could lead to a more favourable
ICER for the strategy with a booster-dose with MenACWY, as
illustrated by our analysis with the epidemiologic data of 2011. By
performing threshold analyses to determine for which meningo-
Cost-Effectiveness of MenACWY Vaccination
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coccal disease incidence the ICER remains below J50,000 per
QALY, we enabled policy makers to make informed decisions
about whether and when to implement a booster dose vaccination
among adolescents.
In addition to a further increase in the incidence of serogroup Y
disease, the potential loss of herd immunity against meningococcal
C disease due to an unprotected adolescent population makes a
booster dose at 12 years of age more favourable. Our scenario
analysis shows that when herd immunity disappeared, MenAC-
WY+MenACWY has the potential to be cost-effective. However,
this scenario may be overrating since herd immunity will most
likely disappear gradually. Moreover, part of the disease incidence
reduction might be contributed to natural fluctuation. To estimate
the effect of herd immunity and its disappearance more precisely,
a transmission dynamic model should be used [35]. Force of
infection is an important dynamic parameter for estimating herd
immunity and in dynamic models the force of infection is allowed
to change contrary to static models [36]. The scenario in which
herd immunity is lost, does not seem unlikely because recent data
from the UK suggests that protective antibody levels have declined
markedly in all immunized cohorts since the time of vaccination
[11]. Without high protective antibody levels a restored circulation
of the bacterium is possible, although this has not been observed
yet in the UK. However, it is difficult to predict when this might
happen, just by the naturally fluctuating incidence of meningo-
coccal disease [33].
For our scenario analysis, we assumed that vaccination at 14
months only would not be sufficient to maintain herd-immunity,
because a dose under the age of 5 years is not likely to maintain
herd immunity as little herd immunity is observed in Spain where
the MenC catch-up program was till the age of 5 years [37]. In
contrast, a booster-dose at 12 years is a good option for
maintaining herd immunity, because vaccinating at around that
age resulted in extended antibody persistence, providing protec-
tion in adolescents, among which meningococcal transmission
rates is most likely high [9]. In addition, the response to a booster-
dose with a MenC vaccine showed an age dependent trend in
children at age of 6 to 12 years, with highest responses in 12 years
old children [10,11].
Experience with the MenC vaccine showed a reduction in
serogroup C disease attack rates in unimmunized individuals and a
significantly lower serogroup C carriage [6,7]. Since it is uncertain
whether a herd immunity effect for vaccination against serogroups
A,W135,Y disease would be invoked by the implementation of
vaccinations at 14 months and 12 years, we estimated ICERs with
and without herd-immunity against serogroups A,W135,Y disease.
Data on the VE was estimated by post-vaccination studies
which calculated VE by the screening method. Because this
method uses data on the amount of cases in the population [38], a
part of the herd immunity effect might be included in our VE
estimate, possibly leading to an underestimation of the initial VE.
The clinical course and outcome of serogroup A, W-135 and Y
disease was assumed to be equal to that of serogroup C disease,
Table 3. Incremental cost-effectiveness ratios and threshold analyses with and without herd-immunity against serogroup AWY.
ICERa [J/QALY (95% CI)] Threshold incidence per 100,000 persons for
J50,000/QALY
Base case incidencea 2011 incidenceb Base casec 2011 scenariod
No herd-immunity against AWY
MenACWY vs MenC c.s. (c.s.-c.s.) c.s. (c.s.-c.s.) N.A. N.A.
MenACWY+MenACWY vs MenC
Waning rate booster 0.04 635,334 (259,672–1,121,856) 473,398 (179,847–849,293) 1.53 0.98
No waning booster 367,978 (151,968–649,963) 307,743 (114,982–554,719) 0.91 0.65
MenACWY+MenACWY vs MenACWY
Waning rate booster 0.04 988,490 (440,833–1,675,575) 621,307 (251,868–1,089,972) 2.37 1.28
No waning booster 518,405 (224,848–887,791) 396,431 (160,174–700,855) 1.28 0.83
MenACWY+MenACWY vs MenACWYe
Waning rate booster 0.04 c.s. (c.s. 23,168) c.s. (c.s. 22,908) N.A. N.A.
No waning booster c.s. (c.s. 23,269) c.s. (c.s. 22,867) N.A. N.A.
Herd-immunity against AWY
MenACWY+MenACWY vs MenC
Waning rate booster 0.04 247,279 (101,873–426,876) 204,170 (76,617–365,845) 0.61 0.43
No waning booster 190,073 (75,665–331,131) 163,264 (59,144–293,917) 0.48 0.35
MenACWY+MenACWY vs MenACWY
Waning rate booster 0.04 359,264 (166,041–593,227) 268,094 (110,297–466,305) 0.87 0.56
No waning booster 267,157 (119,263–447,724) 212,846 (84,860–372,550) 0.66 0.45
QALY= quality adjusted life year, c.s. = cost-saving, N.A. = not applicable.
aBase case incidence (average 2007–2011): 0.10 cases of serogroup A,W135,Y and 0.05 cases of serogroup C per 100,000 persons.
b2011 incidence: 0.11 cases of serogroup A,W135,Y and 0.02 cases of serogroup C per 100,000 persons.
cUsing the average age-distribution of the serogroup A,C,W135 and Y incidence of 2007–2011.
dUsing the age-distribution of the serogroup A,C,W135 and Y incidence of 2011.
eScenario analysis: compared with MenACWY at 14 months with only direct effects of vaccination and the incidence of C of 2001: 2.09 cases of serogroup C per 100,000
persons.
doi:10.1371/journal.pone.0065036.t003
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because limited data for serogroup A, W-135 and Y disease from
the Netherlands is available. Two studies with a relatively low
number of sero-group A, W-135 and Y cases indicate that
serogroup W-135 and Y might be associated with a higher case-
fatality rate [4], more sequelae, septicaemia, and in general a
poorer outcome [39] than serogroup C or B. Therefore we may
have underestimated the cost-effectiveness of the MenACWY
vaccine.
Recently, it has been shown that three years after vaccination of
toddles with MenACWY, antibody persistence was high for
serogroups C, W-135 and Y, but was much lower for serogroup A
[28]. Although this finding may have negative consequences on
the ICER in countries with a high prevalence of serogroup A
disease, it would not affect our results, since serogroup A disease
has not been observed in the Netherlands during the past years
[15].
Serogroup replacement by capsular switching due to vaccina-
tion was not modelled, because there is no evidence that
vaccination with the MenC vaccine is an important driver in
capsule switching of meningococci [40].
The MenACWY conjugate vaccine does not protect against
serogroup B meningococcal (MenB) disease. Recently, a broad-
coverage vaccine with the capacity to protect against MenB
disease (4CMenB, Novartis) was licensed in the European Union
[41]. Although more additional cases of meningococcal disease
could be prevented in the Netherlands with the implementation of
infant vaccination (2, 3, 4+11 mo schedule) against MenB disease
(39 cases prevented in a single birth-cohort followed for 99 years in
the base-case analysis) [42] than with the shift from a MenC
vaccine to the MenACWY vaccine in the NIP, the latter option is
more attractive from a cost-effective point of view [42], since the
broad-coverage vaccine against MenB would be an additional
vaccine instead of a replacement of the MenC vaccine. In
addition, more vaccinations are needed with the MenB vaccine to
confer protection in young children [28,43] The recently licensed
MenB vaccine has not only the capacity to protect against MenB
disease; it might also protect against other meningococcal
serogroups, because the protein antigens are not restricted to
serogroup B meningococci [44]. The coverage against these other
meningococcal serogroups is unclear and protection against these
other serogroups is likely better with monovalent or quadrivalent
Table 4. Disease outcomes and costs associated with
MenACWY vaccination at 14 months only and MenACWY






All 46 40 26
With skin scarring 1 1 0




Deaths 3 3 0
Life years (disc.) 17,225,124 17,225,133 9
QALYs (disc.) 15,482,017 15,482,029 12
Costs (J)
(discounted)
Total costsa 9,356,182 21,039,738 11,683,555
Direct costsb 9,336,046 19,576,633 10,240,587




Productivity losses 20,809 1,463,778 1,442,968
D=difference between the vaccination strategies in respectively disease
outcome and costs,
disc. = discounted, QALY =quality adjusted life year.
aThe total sum of all costs (including vaccination costs).
bDirect costs: total costs minus costs due to productivity losses.
cVaccination costs: costs of the vaccine plus administration and overhead costs.
dIndirect vaccination costs: costs for the treatment of side effects of the
vaccination. Productivity losses due to vaccination and side effects are included
in ‘productivity losses’.
doi:10.1371/journal.pone.0065036.t004
Table 5. Bivariate sensitivity analysis for MenACWY compared with MenC at 14 months.
Incremental cost-effectiveness ratios [J/QALY (95% CI)]
Average duration of protection for MenACWY after vaccination at 14 monthsa
Price differentialb ACWY: 6 y ACWY: 5 y ACWY: 4 y ACWY: 3 y ACWY: 2 y
- J5,- c.s. c.s. c.s. c.s. J907,349c
- J1,- c.s. c.s. c.s. c.s. J170,984c
J0,- c.s. c.s. c.s. c.s. d
J1,- J15,622 J25,162 J46,753 J143,724 d
J2,- J44,576 J63,865 J107,335 J301,923 d
J3,- J73,529 J102,569 J167,918 J460,122 d
J4,- J102,483 J141,273 J228,501 J618,321 d
J5,- J131,347 J179,976 J289,084 J776,520 d
QALY= quality adjusted life year, c.s. = cost-saving. Costve price differential indicates that MenACWY is cheaper than MenC. 14 months in a loss of QALYs if the duration
of protect.
aThe average duration of protection of MenC is held constant at 4 years.
bA negative price differential indicates that MenACWY is cheaper than MenC.
cICER expresses the costs saved per QALY lossed.
dFor these scenarios, MenACWY vaccination at 14 months costs more and saves less QALYs than MenC vaccination.
doi:10.1371/journal.pone.0065036.t005
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conjugated vaccines specifically designed to protect against
meningococcal serogroup A, C, W-135 and Y disease. Therefore,
with the current knowledge, 4CMenB cannot replace routine
infant vaccination with the MenC vaccine. Because the C
component of MenACWY has been shown to be immunologically
non-inferior to that of MenC [25–28], a shift from a MenC
vaccine to this MenACWY vaccine in the NIP might be
considered, especially when the meningococcal serogroup Y
disease incidence keeps increasing in the Netherlands. To our
knowledge, this is the first study which examines the cost-
effectiveness of a MenACWY conjugate vaccine and of introduc-
ing a booster-dose with this vaccine at the age of 12 years in the
Netherlands. Two cost-effectiveness studies on a MenACWY
conjugate vaccine were performed in the United States [45,46].
Both studies found that vaccinating children and adolescents
would reduce substantially the burden of disease but at high costs.
A third study is performed in Canada and is more similar to the
Dutch situation because the comparable immunization program
with respect to meningococcal disease [47]. This study showed an
ICER of $31,000 per QALY for a booster-dose at 12 years with
MenACWY in addition to MenC at 12 months, with MenC at 12
months as comparator. This ICER is much lower than the ICER
calculated with this analysis in the Netherlands. This is mainly due
to the higher incidence of serogroup W135 and Y disease in
Canada [34,47]. In any case, it is difficult to make a good
comparison between these studies just by different discount rates
(differential vs. equal discount rates for money and health) and
differences in incidences in meningococcal disease.
Conclusions
According to the results of this cost-effectiveness analysis,
MenACWY at 14 months is cost-saving compared to MenC at 14
months, mainly due to a lower vaccine price. Adding a booster-
dose with MenACWY at 12 years reduces the burden of disease
but is not cost-effective with the current epidemiology. However,
the scenario with the disappearance of herd immunity shows that
the strategy with a booster-dose with MenACWY at 12 years has
the potential to be cost-effective in the future. For a more precise
estimation of the cost-effectiveness for the prevention of the loss of
herd immunity, a dynamic model should be developed for the
Netherlands.
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